Entellus Medical (ENTL) Getting Somewhat Favorable Press Coverage, Study Finds
Media headlines about Entellus Medical (NASDAQ:ENTL) have been trending somewhat positive on Sunday, according to Accern. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Entellus Medical earned a daily sentiment score of 0.02 on Accern’s scale. Accern also gave media stories about the medical technology company an impact score of 46.7182791532915 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Is Entellus Medical Inc’s (ENTL) Balance Sheet Strong Enough To Weather A Storm? (finance.yahoo.com)
- Edited Transcript of ENTL earnings conference call or presentation 1-Nov-17 8:30pm GMT (finance.yahoo.com)
- Entellus Medical Announces Third Quarter 2017 Financial Results (thestreet.com)
- Entellus Medical, Inc. to Host Earnings Call (baystreet.ca)
- Zacks Investment Research Lowers Entellus Medical, Inc. (ENTL) to Hold (americanbankingnews.com)
Entellus Medical (NASDAQ:ENTL) traded down $0.17 during midday trading on Friday, hitting $17.24. The stock had a trading volume of 115,846 shares, compared to its average volume of 131,269. The company has a current ratio of 3.87, a quick ratio of 3.53 and a debt-to-equity ratio of 0.19. Entellus Medical has a 12-month low of $11.47 and a 12-month high of $20.34.
Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). The firm had revenue of $22.10 million for the quarter, compared to the consensus estimate of $21.87 million. Entellus Medical had a negative net margin of 31.24% and a negative return on equity of 60.10%. Entellus Medical’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.27) earnings per share. analysts forecast that Entellus Medical will post -1.55 EPS for the current fiscal year.
Several research firms recently issued reports on ENTL. Zacks Investment Research cut Entellus Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. BidaskClub raised Entellus Medical from a “buy” rating to a “strong-buy” rating in a report on Friday, July 14th. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Entellus Medical in a report on Wednesday, July 12th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $21.17.
WARNING: “Entellus Medical (ENTL) Getting Somewhat Favorable Press Coverage, Study Finds” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/11/05/entellus-medical-entl-getting-somewhat-favorable-press-coverage-study-finds.html.
In other news, VP Kevin L. Mensink sold 2,500 shares of the company’s stock in a transaction on Friday, October 20th. The stock was sold at an average price of $19.00, for a total value of $47,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Timothy B. Petrick sold 2,000 shares of the company’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $18.00, for a total value of $36,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 92,150 shares of company stock worth $1,740,652 over the last three months. Insiders own 7.70% of the company’s stock.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.